FPFT-2216 exerted stronger growth-inhibitory and CK1α-degrading activities against lymphoid tumor cell lines than thalidomide derivatives (Fig. 1; Table 1). The gene discussed is CSNK1A1; the disease is lymphoid neoplasm.